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ACUTE CORONARY SYNDROMES
Intervention in acute coronary syndromes: do patients
undergo intervention on the basis of their risk characteristics?
The Global Registry of Acute Coronary Events (GRACE)
K A A Fox, F A Anderson Jr, O H Dabbous, P G Steg, J Lo´pez-Sendo´n, F Van de Werf, A Budaj,
E P Gurfinkel, S G Goodman, D Brieger, on behalf of the GRACE investigators
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
See end of article for
authors’ affiliations
. . . . . . . . . . . . . . . . . . . . . . . .
Correspondence to:
Professor Keith A A Fox,
Cardiovascular Research,
University of Edinburgh,
Chancellor’s Building, 49
Little France Crescent,
Edinburgh EH16 4SB, UK;
k.a.a.fox@ed.ac.uk
Accepted 24 May 2006
Published Online First
6 June 2006
. . . . . . . . . . . . . . . . . . . . . . . .
Heart 2007;93:177–182. doi: 10.1136/hrt.2005.084830
Objective: To determine whether revascularisation is more likely to be performed in higher-risk patients and
whether the findings are influenced by hospitals adopting more or less aggressive revascularisation
strategies.
Methods: GRACE (Global Registry of Acute Coronary Events) is a multinational, observational cohort study.
This study involved 24 189 patients enrolled at 73 hospitals with on-site angiographic facilities.
Results: Overall, 32.5% of patients with a non-ST elevation acute coronary syndrome (ACS) underwent
percutaneous coronary intervention (PCI; 53.7% in ST segment elevation myocardial infarction (STEMI)) and
7.2% underwent coronary artery bypass grafting (CABG; 4.0% in STEMI). The cumulative rate of in-hospital
death rose correspondingly with the GRACE risk score (variables: age, Killip class, systolic blood pressure, ST
segment deviation, cardiac arrest at admission, serum creatinine, raised cardiac markers, heart rate), from
1.2% in low-risk to 3.3% in medium-risk and 13.0% in high-risk patients (c statistic = 0.83). PCI procedures
were more likely to be performed in low- (40% non-STEMI, 60% STEMI) than medium- (35%, 54%) or high-
risk patients (25%, 41%). No such gradient was apparent for patients undergoing CABG. These findings were
seen in STEMI and non-ST elevation ACS, in all geographical regions and irrespective of whether hospitals
adopted low (4.2233.7%, n = 7210 observations), medium (35.7251.4%, n = 7913 observations) or
high rates (52.6277.0%, n = 8942 observations) of intervention.
Conclusions: A risk-averse strategy to angiography appears to be widely adopted. Proceeding to PCI relates
to referral practice and angiographic findings rather than the patient’s risk status. Systematic and accurate
risk stratification may allow higher-risk patients to be selected for revascularisation procedures, in contrast to
current international practice.
E
vidence from randomised trials and meta-analyses sug-
gests a reduction in adverse outcomes in patients with an
acute coronary syndrome (ACS) assigned to an early
invasive strategy.1–7 In the recently published ICTUS (Invasive
versus Conservative Treatment in Unstable Coronary
Syndromes) study,8 patients with non-ST elevation ACS
randomly allocated to early invasive management had a similar
mortality to those who underwent selective invasive manage-
ment, and the rates of intervention were high (79% v 54%,
respectively).
The ongoing GRACE (Global Registry of Acute Coronary
Events) is the largest multinational cohort study of patients
hospitalised with the spectrum of ACS. The objective of this
study was to investigate the use of revascularisation strategies
according to the risk status of the patients at presentation.
Further, the study aimed at determining whether practice
differs according to geographic regions and whether hospitals
(all with on-site angiographic facilities) practise higher,
medium or lower rates of revascularisation. If practice follows
the results of randomised trials3 4 and guidelines,9 10 then the
highest rates of revascularisation would be observed in higher-
risk patients.
METHODS
Full details of the GRACE methods have been published.11–13
GRACE is designed to reflect an unbiased population of
patients with ACS, irrespective of geographical region. A total
of 106 hospitals from 14 countries in North and South America,
Europe, Australia and New Zealand have participated in this
prospective observational study.
Patients entered in the study had to be at least 18 years old
and alive at the time of hospital presentation, be admitted with
ACS as the presumptive diagnosis (with symptoms consistent
with acute ischaemia) and have at least one of the following:
ECG changes consistent with ACS, serial increases in serum
biochemical markers of cardiac necrosis and documentation of
coronary artery disease. The qualifying ACS must not have been
precipitated by significant non-cardiovascular co-morbidity (for
example, trauma or surgery). At about six months after hospital
discharge, patients were followed up to ascertain the occur-
rence of selected long-term study outcomes. Where required,
study investigators received approval from their local hospital
ethics or institutional review board.
The study aimed at enrolling an unbiased population and
sites were encouraged to recruit the first 10 to 20 consecutive
eligible patients each month. Data were collected by trained
coordinators on standardised case report forms. Demographic
characteristics, medical history, presenting symptoms, duration
of prehospital delay, biochemical and ECG findings, treatment
practices and hospital outcome data were collected.
Standardised definitions of all patient-related variables, clinical
Abbreviations: CABG, coronary artery bypass grafting; GRACE, Global
Registry of Acute Coronary Events; ICTUS, Invasive versus Conservative
Treatment in Unstable Coronary Syndromes; NSTEMI, non-ST segment
elevation myocardial infarction; PCI, percutaneous coronary intervention;
STEMI, ST segment elevation myocardial infarction
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diagnoses, and hospital complications and outcomes were
used.12 All patients were assigned, on the basis of predefined
criteria, to one of the following categories: ST segment elevation
myocardial infarction (STEMI), non-ST segment elevation
myocardial infarction (NSTEMI) or unstable angina.12
Patients with STEMI, NSTEMI or unstable angina were
characterised on the basis of their discharge diagnosis. STEMI
was diagnosed when patients had a new or presumed new ST
segment elevation > 1 mm in any location, or new left bundle
branch block on the index or qualifying ECG with at least one
positive cardiac biochemical marker of necrosis (including
troponin measurements, whether qualitative or quantitative).
In cases of NSTEMI, at least one positive cardiac biochemical
marker of necrosis without new ST segment elevation seen on
the index or qualifying ECG had to be present. Unstable angina
was diagnosed when serum biochemical markers indicative of
myocardial necrosis in each hospital’s laboratory were below
the diagnostic threshold for infarction. Patients originally
admitted because of unstable angina but who developed
myocardial infarction during the hospital stay were classified as
having a myocardial infarction (please refer to www.outcomes.
org/grace for full definitions).
To avoid the possible confounding influence of community
hospital referral practice, only hospitals with direct access to a
catheterisation laboratory were included in this analysis.
Patients were stratified according to their level of risk at
presentation according to the GRACE risk model for in-hospital
death.14
In-hospital outcomes were death; death or myocardial
infarction beyond the first 24 h; or reinfarction, stroke
(haemorrhagic, non-haemorrhagic or other, defined according
to the occurrence of typical neurological signs and symptoms)
and major bleeding (defined as life-threatening bleeding
requiring transfusion of > 2 units of packed red blood cells or
resulting in an absolute decrease in packed cell volume > 10%
or death, or haemorrhagic/subdural haematoma). Outcomes
that occurred during the six months after hospital discharge
were death, unscheduled rehospitalisation for heart disease,
myocardial infarction and stroke.
Role of the funding source
The sponsor, sanofi-aventis, had no involvement in the
collection, analysis and interpretation of data; in the writing
of the report; and in the decision to submit the paper for
publication. The design, conduction and interpretation of
GRACE are undertaken by an independent steering committee.
RESULTS
Patient and hospital characteristics
A total of 24 189 patients with ACS were enrolled in the GRACE
registry between April 1999 and September 2004. Table 1
outlines the patients’ baseline characteristics according to the
GRACE risk score. Data were collected from 73 hospitals with
direct access to catheterisation facilities and these were divided
into tertiles according to the rates of intervention. A total of
7210 observations were reported for hospitals in the lowest
tertile of intervention rates (‘‘low rate’’), 7913 for the middle
tertile (‘‘medium rate’’) and 8942 for the highest tertile (‘‘high
rate’’) for percutaneous coronary intervention (PCI) or coronary
artery bypass grafting (CABG). Complete data were not
available for 124 patients.
The population was stratified into low-, medium- and high-
risk tertiles according to the GRACE risk score14 (table 1). A
gradient of risk characteristics was observed for both non-ST
elevation ACS and STEMI.
Table 1 Baseline characteristics according to GRACE risk score for patients presenting with an acute coronary syndrome
Unstable angina/NSTEMI STEMI
Low risk Medium risk High risk p Value Low risk Medium risk High risk p Value
Number 3944 5440 5704 4119 2623 2359
Men 2755 (70%) 3637 (67%) 3431 (61%) ,0.001 3318 (81%) 1773 (68%) 1302 (56%) ,0.001
Mean age (years) 54 65 75 ,0.001 55 69 77 ,0.001
Medical history
Angina 2463 (63%) 3707 (69%) 3755 (66%) ,0.001 1592 (39%) 1084 (42%) 1085 (46%) ,0.001
Smoker, current/former 2578 (66%) 3195 (59%) 2826 (50%) ,0.001 3021 (74%) 1527 (59%) 1066 (46%) ,0.001
Diabetes 907 (23%) 1443 (27%) 1664 (29%) ,0.001 664 (16%) 598 (23%) 661 (28%) ,0.001
Prior MI 1189 (30%) 1934 (36%) 2350 (41%) ,0.001 673 (16%) 544 (21%) 639 (27%) ,0.001
CHF 166 (4.2%) 441 (8.2%) 1195 (21%) ,0.001 75 (2.0%) 139 (5.3%) 362 (16%) ,0.001
Prior PCI 967 (25%) 1453 (27%) 1281 (23%) ,0.001 433 (11%) 271 (10%) 246 (11%) 0.98
Prior CABG 549 (14%) 1051 (19%) 1195 (21%) ,0.001 175 (4.3%) 169 (6.5%) 213 (9.1%) ,0.001
PVD 252 (6.4%) 598 (11%) 837 (15%) ,0.001 189 (4.6%) 212 (8.2%) 246 (11%) ,0.001
Hypertension 2375 (61%) 3424 (63%) 3787 (67%) ,0.001 1889 (46%) 1503 (58%) 1408 (60%) ,0.001
Atrial fibrillation 120 (3.1%) 355 (6.6%) 887 (16%) ,0.001 76 (1.9%) 146 (5.6%) 278 (12%) ,0.001
Prior drugs
Aspirin 1757 (45%) 2960 (54%) 3077 (54%) ,0.001 790 (19%) 699 (27%) 756 (32%) ,0.001
ACE inhibitor 1005 (26%) 1627 (30%) 1943 (34%) ,0.001 592 (14%) 512 (20%) 524 (22%) ,0.001
Oral b blocker 1440 (37%) 2226 (41%) 2272 (40%) ,0.001 728 (18%) 545 (21%) 524 (22%) ,0.001
Statin 1162 (30%) 1877 (35%) 1795 (32%) ,0.001 555 (14%) 402 (15%) 340 (15%) 0.099
Presentation characteristics
Mean pulse (beats/min) 75 75 84 ,0.001 75 77 90 ,0.001
Mean SBP (mm Hg) 156 145 134 ,0.001 146 137 125 ,0.001
Mean initial creatinine (mmol/l) 88.4 97.2 124 ,0.001 88.4 97.2 124 ,0.001
Killip class
I 3889 (98.6%) 5104 (93.8%) 3922 (69%) ,0.001 4005 (97%) 2302 (88%) 1174 (50%) ,0.001
II 54 (1.4%) 315 (5.8%) 1408 (25%) 113 (3.0%) 300 (11.4%) 762 (32%)
III (pulmonary oedema) 0 20 (0.4%) 320 (6.0%) 0 19 (0.7%) 282 (12%)
IV (cardiogenic shock) 0 1 (0%) 54 (1.0%) 0 2 (0.1%) 141 (6.0%)
Cardiac arrest 0 6 (0.1%) 83 (1.5%) ,0.001 10 (0.2%) 41 (1.6%) 183 (7.8%) ,0.001
Positive initial cardiac markers 900 (23%) 1611 (30%) 2741 (48%) ,0.001 1602 (39%) 1547 (59%) 1701 (72%) ,0.001
ACE, angiotensin-converting enzyme; CABG, coronary artery bypass grafting; CHF, congestive heart failure; GRACE, Global Registry of Acute Coronary Events; MI,
myocardial infarction; NSTEMI, non-ST segment elevation myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; SBP,
systolic blood pressure; STEMI, ST segment elevation myocardial infarction.
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In-hospital management
Overall, 32.5% of patients with NSTEMI or unstable angina
underwent PCI and 7.2% underwent CABG. Rates of revascu-
larisation were high for patients with STEMI (53.7% PCI and
4.0% CABG). The likelihood of a patient undergoing PCI was
related to the patient’s risk status but the relationship was
inverse (fig 1). No such gradient was apparent for patients
undergoing CABG. Findings were similar for patients with
STEMI and for non-ST elevation ACS. More high-risk than low-
risk patients underwent echocardiography, but the converse
was true for both exercise testing and angiography. More low-
risk (31.2% primary PCI, 29.5% fibrinolysis) than medium-risk
(22.7%, 18.4%, respectively) and high-risk (15.1%, 9.2%,
respectively) patients underwent reperfusion (table 2). With
the exception of low molecular weight heparin, other antith-
rombotic drugs were given to more low-risk than high-risk
Table 2 In-hospital management according to GRACE risk score for patients presenting with an acute coronary syndrome
Unstable angina/NSTEMI STEMI
Low risk Medium risk High risk p Value Low risk Medium risk High risk p Value
Number 3944 5440 5704 4119 2623 2359
Cardiac catheterisation 2836 (72%) 3689 (68%) 2894 (51%) ,0.001 3236 (79%) 1937 (74%) 1342 (57%) ,0.001
PCI 1554 (40%) 1907 (35%) 1426 (25%) ,0.001 2466 (60%) 1421 (54%) 959 (41%) 0.98
CABG 298 (7.6%) 425 (7.9%) 361 (6.4%) 0.006 162 (4.0%) 108 (4.2%) 86 (3.7%) 0.67
Fibrinolytics 113 (2.9%) 103 (1.9%) 108 (1.9%) 0.001 1538 (38%) 828 (32%) 445 (19%) ,0.001
Exercise tolerance test 977 (25%) 1205 (23%) 915 (16%) ,0.001 807 (20%) 414 (16%) 238 (10%) ,0.001
Echocardiography 2096 (54%) 2784 (52%) 3250 (58%) ,0.001 2985 (74%) 1982 (76%) 1815 (78%) 0.002
In-hospital drugs
Aspirin 3705 (94%) 5080 (93%) 5136 (90%) ,0.001 3948 (96%) 2490 (95%) 2147 (91%) ,0.001
Thienopyridine 2009 (52%) 2627 (49%) 2292 (41%) ,0.001 2543 (62%) 1485 (57%) 1013 (44%) ,0.001
UFH 1956 (50%) 2496 (47%) 2627 (47%) 0.001 2552 (63%) 1527 (59%) 1280 (55%) ,0.001
LMWH 2263 (58%) 3145 (58%) 3160 (56%) 0.016 2052 (50%) 1447 (56%) 1251 (54%) ,0.001
GP IIb/IIIa inhibitor 1008 (26%) 1197 (22%) 1002 (18%) ,0.001 1669 (41%) 914 (35%) 659 (28%) 0.099
ACE inhibitor 2157 (55%) 2911 (54%) 3234 (57%) 0.004 2796 (68%) 1861 (71%) 1589 (68%) 0.01
b blocker 3352 (85%) 4533 (84%) 4251 (75%) ,0.001 3706 (90%) 2217 (85%) 1615 (69%) ,0.001
Calcium antagonist 1120 (29%) 1745 (32%) 1936 (34%) ,0.001 578 (14%) 490 (19%) 425 (18%) ,0.001
ACE, angiotensin-converting enzyme; CABG, coronary artery bypass grafting; GP, glycoprotein; GRACE, Global Registry of Acute Coronary Events; LMWH, low
molecular weight heparin; MI, myocardial infarction; NSTEMI, non-ST segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST
segment elevation myocardial infarction; UFH, unfractionated heparin.
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Figure 1 Proportion of patients according
to GRACE (Global Registry of Acute
Coronary Events) risk score, relation
between GRACE risk score and crude
predicted death rate (curved line), and use of
intervention according to decile of GRACE
risk score undergoing intervention
(histogram). (Patients with a score , 80
were aggregated, and those with a rate
. 280 were aggregated; these groups
represent 0.6% and 0.7% of the data,
respectively). Catheterisation, p = 0.0002;
percutaneous coronary intervention (PCI),
p = 0.03; coronary artery bypass grafting
(CABG), p = 0.01. GRACE risk score
adapted from Granger et al14.
Determination of non-eligibility for
catheterisation, PCI or CABG: in-hospital or
history of haemorrhagic stroke, and age
. 75 years, renal insufficiency (creatinine
. 265 mmol/l).
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patients (table 2). Thienopyridines, unfractionated heparin and
glycoprotein IIb/IIIa inhibitors were all given to more low- than
medium-risk patients, consistent with the gradient in rates of
angiography and PCI (table 2).
In-hospital outcomes
The rates of in-hospital death among low-, medium- and high-
risk categories of patients were highly consistent with those
predicted by the GRACE risk model14 (3.0% observed death rate
for patients with non-ST elevation ACS v 3.8% predicted; 7.0%
observed death rate for patients with STEMI v 5.3% predicted).
The risk of death ranged from 1.2% for low-risk to 3.3% for
medium-risk and 13.0% for high-risk patients. Fig 1 shows the
proportions of patients enrolled in GRACE according to their
risk score and the relation between risk score and crude
predicted death rate. The incidence of in-hospital stroke was
greatest among high-risk patients with STEMI treated at
hospitals with a high rate of intervention (1.8%) compared
with hospitals with medium (1.4%) or low (1.6%) rates of
intervention. The incidence of stroke was lower among patients
with NSTEMI than among those with STEMI (0.7% v 1.2% in
high-risk patients, and 0.3% v 1.0% in low- to medium-risk
patients).
Fig 2A shows the relationship between patients’ baseline risk
status (in tertiles) and the observed rates of in-hospital death,
and death or myocardial infarction beyond the first 24 h or
reinfarction. Similarly, fig 2B shows a direct relationship
between baseline risk and increasing frequency of stroke and
major bleeding.
To determine whether the relationship between risk and
rates of revascularisation was influenced by whether hospitals
adopted a more or less aggressive angiographic strategy,
hospitals were divided into tertiles according to rates of
angiography (53% low, 73% medium and 88% high rates).
The inverse relationship between risk status of the patient at
presentation and likelihood of proceeding to PCI was indepen-
dent of whether hospitals adopted more or less aggressive
angiography strategies (fig 3). Further, the findings were
consistent across geographic regions and healthcare systems.
DISCUSSION
On the basis of evidence from randomised trials of interven-
tional versus conservative strategies in ACS,1–5 European and
North American guidelines advocate revascularisation for
moderate- or higher-risk patients, but not for low-risk
patients.9 10 Similarly, in studies of STEMI, subgroup analysis
shows that the absolute benefits of revascularisation are
highest among patients with more extensive infarction.15
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Clinical practice would therefore be expected to reflect this
evidence. In contrast, we saw the opposite in our study. We
observed an inverse relationship between the rate of PCI (or the
rate of angiography) and the risk status of the patient,
irrespective of whether the patient had unstable angina,
NSTEMI or STEMI. We saw no such inverse relationship
between risk status and rate of CABG, suggesting that different
criteria are applied in the decision to proceed to CABG or to PCI.
Higher-risk patients were as likely as lower-risk patients to be
referred for CABG. In most instances the interventionist
undertaking the diagnostic angiography would have made the
decision to proceed to PCI,16 whereas the decision to perform
CABG would have required discussion with cardiac surgeons.
The striking inverse relationship between risk status and
performance of angiography (p , 0.001; table 2) indicates that
clinicians responsible for the referral process apply a risk-averse
strategy before obtaining information from coronary angiogra-
phy. With the exception of low molecular weight heparin,
antithrombotics were given to more low-risk than medium- or
high-risk patients, consistent with the rates of angiography and
PCI.
Patients with more extensive co-morbidity may be expected
not to be candidates for CABG, and a proportion of such
patients would not be candidates for PCI. However, the
justification for the higher rate of PCI among low-risk patients
than among medium-risk patients is not apparent. The issue
has been discussed in the context of the operator’s decision to
proceed to PCI on the basis of findings at angiography.16 In fig 1,
the results are analysed according to deciles of GRACE risk
score,14 limited to patients without renal insufficiency (creati-
nine . 265 mmol/l) and excluding patients older than 75 years
(as a surrogate for co-morbidity). The relation between risk
status and angiography, PCI or CABG was not altered by these
exclusions.
In settings where rates of angiography are lower, perhaps
related to availability of personnel and resources, a more
selective strategy for PCI might have been expected to be
adopted (favouring those at higher risk of death or myocardial
infarction). However, the relationship is no different from that
in hospitals with medium or high rates of angiography. The
findings suggest that a risk-averse strategy is widely adopted
for angiography in ACS. The findings are consistent, irrespec-
tive of whether sites adopt a more or less aggressive strategy for
revascularisation and irrespective of healthcare system and
geographic region. As fig 3 shows, hospitals in the highest
tertile for rates of angiography have PCI rates more than
twofold greater than those in the lowest tertile for respective
risk groups (high risk 77.7% v 37.2% PCI; medium risk 69.2% v
29.1%; low risk 50.7% v 16.0%). Hence, if patient contra-
indications were responsible for the findings, this would not
explain how the more aggressive centres undertake much
higher rates of angiography and intervention than less
aggressive centres for risk-matched patients. The consistency
of inverse relationship between risk and invasive procedures
suggests that the observations are widely applicable, rather
than determined by resource allocation or staff availability.
Paradoxically, this pattern of practice is not supported by trial
evidence1–7 or by guidelines for clinical practice.9 10
Although we excluded patients first admitted to community
hospitals from our analysis, our findings may provide some
explanation for those of Van de Werf et al.17 In their study of
patients enrolled in the GRACE database, patients admitted to
hospitals with catheterisation facilities were more likely to
undergo intervention than were patients admitted to sites
without such facilities, but they had a higher risk of death
within six months of discharge. This later risk may reflect
hazards of intervention (but very modest gain) among low-risk
patients. The randomised trial evidence and the guidelines
support the use of revascularisation in moderate- or high-risk
patients, irrespective of the presence of on-site catheterisation
facilities.
Strengths and limitations
GRACE is the largest multinational registry to study the
complete spectrum of patients with an ACS. Standardised
criteria are used for defining ACS and hospital outcomes, and
rigorous quality control and audit measures are used.
Nevertheless, the GRACE registry shares the limitations of
observational studies. This analysis is confined to centres with
direct access to angiographic facilities and therefore excludes
patients who presented to district or community hospitals
without interventional facilities. Thus, the findings are not
confounded by issues relating to interhospital transfer of
patients. Restriction of the registry to patients who are
admitted may have resulted in the exclusion of patients dying
early in the emergency room, but such patients are very
unlikely to be selected for revascularisation. The participating
clusters reflect regional practices and outcomes but do not
necessarily reflect practice for specific countries. Among the
highest-risk patients a significant proportion may not be
technically suitable for revascularisation (for example, in the
highest decile of risk; fig 2) and in some patients the balance of
co-morbidity may be such that revascularisation may not offer
an acceptable level of periprocedural risk. However, this cannot
explain the lower rates of PCI among medium than among low-
risk patients or the highly significant (p = 0.0008) inverse
relationship between rates of angiography and risk status
(table 2).
In conclusion, systematic and accurate risk stratification may
allow higher-risk patients to be selected for revascularisation
procedures, in contrast to current international practice.
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